Skip to Content
Merck

R8657

Razoxane

>98% (HPLC)

Synonym(s):

(±)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane, (±)-1,2-Bis(3,5-dioxopiperazinyl)propane, 1,2-Bis(3,5-dioxo-1-piperazinyl)propane, 4,4′-Propylenebis(2,6-piperazinedione), ICI 59118, ICRF 159, NSC 129943, Razoxin, Tepirone, Troxozone

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C11H16N4O4
CAS Number:
Molecular Weight:
268.27
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
244-379-2
MDL number:
Assay:
>98% (HPLC)
Form:
solid
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

assay

>98% (HPLC)

form

solid

solubility

DMSO: 40 mg/mL

storage temp.

room temp

SMILES string

CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

InChI

1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)

InChI key

BMKDZUISNHGIBY-UHFFFAOYSA-N

Biochem/physiol Actions

Razoxane is clinically active against angiogenesis and metastasis. Razoxane specifically inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor). It is an antimitotic agent with immunosuppressive properties. Razoxane inhibits blood-borne and lymphatic metastases in different experimental models. Studies have shown that razoxane inhibits specifically the vasculogenic mimicry of B16F10 melanoma cells.
Razoxane is clinically active against angiogenesis and metastasis; inhibits topoisomerase II without inducing DNA strand breaks (topo II catalytic inhibitor).

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

W Rhomberg et al.
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 175(3), 102-104 (1999-03-27)
Angiosarcomas of the heart are rare neoplasms bearing an unfavorable prognosis. In recent series, the median survival is about 5 months. The response to radiation therapy is uncertain. A 65-year-old copper smith with an angiosarcoma of the right atrium and
Dynamics of tumour angiogenesis: effect of razoxane-induced growth rate slowdown.
K Hellmann
Clinical & experimental metastasis, 20(2), 95-102 (2003-04-23)
Annie Calvé et al.
Canadian journal of physiology and pharmacology, 90(11), 1527-1534 (2012-11-28)
Childhood cancer survivors can develop significant cardiac dysfunction in adulthood as a consequence of their cancer treatment. Studies have linked heart failure during pregnancy to childhood doxorubicin (DOX) exposure. We hypothesized that DOX injection would reduce cardiac function peripartum and
M Doornaert et al.
Acta chirurgica Belgica, 113(1), 1-7 (2013-04-05)
Extravasation is a devastating complication of intravenous therapy that develops when a drug infiltrates the interstitial tissue surrounding the vein. Due to the uncertain and possibly dramatic outcome, early recognition and adequate treatment with the aid of a standardized protocol
Steven E Lipshultz et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(10), 1042-1049 (2012-03-01)
Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy. Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service